Biotech Stocks Facing FDA Decision In May 2020

2 / 10
Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma

The New Drug Application for Dasotraline, a novel dopamine and norepinephrine reuptake inhibitor for the treatment of patients with moderate-to-severe binge eating disorder, is under FDA review, with a decision expected on May 14, 2020.

Dasotraline is being developed by Sunovion Pharmaceuticals Inc., an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (DNPUF.OB).

Binge eating disorder (BED), is characterized by recurrent and persistent episodes of binge eating, defined as consuming large quantities of food in a short period of time, perception of loss of control during the episode, and intense feelings of shame, guilt, and embarrassment afterwards. An estimated 4.1 million Americans are affected by BED.

DNPUF.OB closed Monday's (Apr.27, 2020) trading at $13.85, up 6.13%.